Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
Epistemonikos ID: dd387660bbb2f14d9f57dcc294f6c53755b17ee2
First added on: Feb 19, 2024